Key facts
- Arine’s last known valuation is $520.0M (Jun 2025).
- It has raised $63.6M; the latest was Later Stage VC ($30.0M) in Jun 2025.
- Notable investors include MBX Capital, Town Hall Ventures, Kaiser Permanente Ventures, New Leaf Venture, 111 West Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Arine
- ·The full record, as it builds
Funding rounds
No funding rounds for Arine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Arine
Developer of a medication management platform designed to improve health and quality of life. The company's medication optimization platform aggregates and analyzes clinical, social, and behavioral data to identify and address gaps in patient care on behalf of payors and risk-bearing providers, enabling patients to get improved outcomes and lower costs for care.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2017
- Employees
- 200
- Website
- arine.io/
- Ownership
- Privately Held (backing)
Arine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arine in its N-PORT filings yet. We sweep new filings monthly.